Set to expand the wealth of knowledge and further pioneer the care and treatment of men with prostate cancer, Dr Stricker is this year engaging in a new clinical trial. Having commenced in early 2012 the trial focuses on low risk prostate cancers and the role of Magnetic Resonance Imaging (MRI).
Open to all men with low risk prostate cancers who are engaged in active surveillance, the result will add more scientific information to assist patients in choosing the most appropriate treatment. In particular, the trial will focus on the way in which active surveillance and MRI are used to assess the size and progression of the cancer as well as to minimise the number of biopsies.
It is anticipated that the results of the clinical trial will be available in two years.
Dr Stricker is recognised by Device Technologies for having performed over 700 robotic surgeries. He is presented with the 'Club 700' certificate by Peter Ord of Device Technologies Australia.
On the 3 November 2011 Dr Phillip Stricker completed his 700th robotic case. Dr Stricker’s robotic results show a 96.5% clearance rate in the eradication of early stage prostate cancer and 86% clearance rate in overall cancers.
Click here for more on Dr Stricker’s robotic surgery results.
Dr Stricker has commenced a new form of laser therapy for benign prostatic hyperplasia using the biolitic laser technology. This is the first time this has been used in Australia and Dr Stricker is initially performing a trial at St Vincent's.